You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 28, 2012

PLC Life Sciences Multi-Jurisdictional Guide 2012 – Vietnam Chapter

Practical Law Company

With the tightening of budgets and increased scrutiny by the Ministry of Health, this article delves into the practicability of Vietnam’s regulatory framework governing the life sciences industry. Ranging from the quality of national healthcare, manufacturing authorization, marketing, and pricing of medicinal products, to the intellectual property surrounding each product and the scope of product liability law in this industry, this Q&A chapter provides a detailed overview of the effect of key legislation and the power of regulatory authorities. In particular, the chapter covers:

  • Pricing Structure: Costs and state funding of medicinal products and national healthcare
  • Manufacturing: Authorization, conditions, fees, and validity of licenses
  • Marketing: Fees, conditions, authorization, packaging requirements, foreign marketing authorizations, parallel imports, and restrictions such as marketing on the internet
  • Traditional Medicine: Manufacturing and marketing regulations
  • Patent Law: Conditions, patentable products, scope of protection, validity, revocation, infringement, and remedies available
  • Trademark Law: Conditions, scope of protection, duration of protection, revocation, infringement, remedies available, and relevant international conventions
  • Product Liability Law: Key legislation, the substantive test, procedures of bringing a claim, defenses and remedies available, limitation periods, and parties liable under the Consumer Protection Law
  • Proposals for Reform: The Draft Law on Advertisement, and further guidance through implementing circulars

This chapter was published by Practical Law Company, a leading provider of legal guidance, analysis, and market intelligence in up to 30 jurisdictions.

RELATED INSIGHTS​ 

September 4, 2019
The 2019 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with its Pharmaceutical Intellectual Property and Competition Law in Cambodia chapter written by practitioners from Tilleke & Gibbins’ Phnom Penh office.The guide is a Q&A-style overview of the regulatory frameworks for the life sciences industries across jurisdictions worldwide. This chapter on pharmaceutical IP and competition law in Cambodia addresses the following issues in the country’s legal landscape for life sciences:
September 3, 2019
On February 19, 2019, by amending the Narcotics Act B.E. 2522, Thailand caught the cannabis industry by surprise and became the first Asia-Pacific country to legalize medicinal cannabis. While hemp had been approved for use in industry since 2018 (see here), the amendment of the Narcotics Act B.E. 2522, providing for a Thai FDA registration pathway for medicinal cannabis, was largely unexpected.   
May 21, 2019
On April 16, 2019, the Drug Act (No. 6) B.E. 2562 was published in the Government Gazette, amending the previous drug registration processes, clinical research processes, and fee schedules. The changes will apply to all pending applications and those filed from October 13, 2019 onward.New Requirements for RegistrationAn additional requirement has been added to the registration process for new drugs. Along with the drug registration dossier, the following documents must now be submitted for each drug classification:
April 23, 2019
Due to significant changes to the intellectual property (IP) landscape, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) indeed poses major challenges to Vietnam in implementing its obligations. Most of the obligations aim to enhance protection for IP proprietors. This will have a particular impact on the life science sectors, benefitting foreign pharmaceutical and agrochemical companies but reducing opportunities, at least in the short-term, for Vietnamese companies.